Origin Therapeutics Holdings (XCNQ:ORIG) Debt-to-EBITDA : 0.00 (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Origin Therapeutics Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Origin Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was C$0.00 Mil. Origin Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was C$0.00 Mil. Origin Therapeutics Holdings's annualized EBITDA for the quarter that ended in Jun. 2023 was C$-0.37 Mil. Origin Therapeutics Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Origin Therapeutics Holdings's Debt-to-EBITDA or its related term are showing as below:

XCNQ:ORIG's Debt-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.69
* Ranked among companies with meaningful Debt-to-EBITDA only.

Origin Therapeutics Holdings Debt-to-EBITDA Historical Data

The historical data trend for Origin Therapeutics Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Origin Therapeutics Holdings Debt-to-EBITDA Chart

Origin Therapeutics Holdings Annual Data

Trend

Sep21

Sep22

Debt-to-EBITDA

N/A

Origin Therapeutics Holdings Quarterly Data
	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-EBITDA	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Origin Therapeutics Holdings's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Origin Therapeutics Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Origin Therapeutics Holdings's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Origin Therapeutics Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Origin Therapeutics Holdings's Debt-to-EBITDA falls into.

Origin Therapeutics Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Origin Therapeutics Holdings's Debt-to-EBITDA for the fiscal year that ended in Sep. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-1.017
	=	0.00

Origin Therapeutics Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-0.368
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.

Origin Therapeutics Holdings (XCNQ:ORIG) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Origin Therapeutics Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Origin Therapeutics Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.